US Patent

US8282967 — Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications

Composition of Matter · Assigned to University of North Carolina at Chapel Hill · Expires 2026-05-30 · 0y remaining

Vulnerability score 35/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects the composition of matter of nitric oxide-releasing particles for delivering nitric oxide in biomedical and pharmaceutical applications.

USPTO Abstract

The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications.

Drugs covered by this patent

berdazimer-sodium (BERDAZIMER SODIUM)

Patent Metadata

Patent number: US8282967
Jurisdiction: US
Classification: Composition of Matter
Expires: 2026-05-30
Drug substance claim: Yes
Drug product claim: No
Assignee: University of North Carolina at Chapel Hill
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.